[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354280-105":59,"doc-detail-354280-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","fusobacterium-nucleatum-in-cancer-interactions-with-microbiota-tumour-colonisation-and-cancer-progression","Fusobacterium nucleatum in cancer - Interactions with microbiota, tumour colonisation and cancer progression","","Growing evidence from multi-cancer cohort studies identifies the oral pathobiont Fusobacterium nucleatum as an emerging microbial contributor to cancer progression. Higher intratumoral abundance has been reported across multiple cancer types and correlates with worse clinicopathological features, treatment resistance, metastasis, and poor prognosis. Advances in microbiome profiling, spatial analysis, and single-cell technologies clarify its tumour entry, colonisation ecology, host interactions, and effects on signalling, inflammation, immune evasion, and therapy response.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/fusobacterium-nucleatum-in-cancer-interactions-with-microbiota-tumour-colonisation-and-cancer-progression/354280/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/fusobacterium-nucleatum-in-cancer-interactions-with-microbiota-tumour-colonisation-and-cancer-progression/354280.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which cancers show increased intratumoral Fusobacterium nucleatum abundance, according to the abstract?","Question",{"text":113,"@type":114},"Increased intratumoral abundance of Fusobacterium nucleatum has been reported in colorectal, breast, esophageal, pancreatic, oral, and gastric cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does Fusobacterium nucleatum promote cancer progression as summarized in the graphical abstract and key points?",{"text":118,"@type":114},"It promotes cancer progression through adhesion, inflammation, immune evasion, epigenetic remodelling, and metastasis.",{"name":120,"@type":111,"acceptedAnswer":121},"What determines Fusobacterium nucleatum’s effects on therapy response?",{"text":122,"@type":114},"Its effects on therapy response are described as tumour-context dependent, with emphasis on chemotherapy, radiotherapy, and immunotherapy responses.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354280,1790210826,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","DOI: 10.1002/ctm2.70704  \nREVIEW  \nFusobacterium nucleatum in cancer: Interactions with microbiota, tumour colonisation and cancer progression  \nFeng Zhao1,2  Rui An2, 3  Shaobo Yu2, 3  Yilei Ma2, 3  Wangwang Liu1   Caixia Sheng1  Xinyou Xie2, 3  Jun Zhang2, 3   \n1 Department of pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China  \n2 Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Hangzhou, Zhejiang, China  \n3 Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China  \nCorrespondence  \nJun Zhang and Xinyou Xie, Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou 310000, Zhejiang, China. [Email:](Email: jameszhang2000@zju.edu.cn and)[ jameszhang2000@zju.edu.cn](Email: jameszhang2000@zju.edu.cn and)[ and](Email: jameszhang2000@zju.edu.cn and)[ ](Email: jameszhang2000@zju.edu.cn and)[scottxie@zju.edu.cn](scottxie@zju.edu.cn)  \nGraphical Abstract  \n1. F. nucleatum colonises tumours through mucosal translocation, adjacenttissue migration and hematogenous dissemination.  \n2. It promotes cancer progression via adhesion, inflammation, immune evasion, epigenetic remodelling and metastasis.  \n3. Its effects on therapy response are tumour-context dependent.  \n4. Microbiome-guided targeting may enable precision oncology.  \nDOI: 10.1002/ctm2.70704  \nREVIEW  \nFusobacterium nucleatum in cancer: Interactions with microbiota, tumour colonisation and cancer progression  \nFeng Zhao1,2  Rui An2, 3  Shaobo Yu2, 3  Yilei Ma2, 3  Wangwang Liu1   Caixia Sheng1  Xinyou Xie2, 3  Jun Zhang2, 3   \n1 Department of pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China  \n2 Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Hangzhou, Zhejiang, China  \n3 Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China  \nCorrespondence  \nJun Zhang and Xinyou Xie, Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou 310000, Zhejiang, China. [Email:](Email: jameszhang2000@zju.edu.cn and)[ jameszhang2000@zju.edu.cn](Email: jameszhang2000@zju.edu.cn and)[ and](Email: jameszhang2000@zju.edu.cn and)[ ](Email: jameszhang2000@zju.edu.cn and)[scottxie@zju.edu.cn](scottxie@zju.edu.cn)  \nFunding information  \nNational Natural Science Foundation of China, Grant/Award Numbers: 82172362, 81800023  \nAbstract  \nBackground: Growing evidence from multi-cancer cohort studies has positioned the oral pathobiont Fusobacterium nucleatum (F. nucleatum) as an emerging microbial contributor to cancer progression. Increased intratumoral abundance ofF. nucleatum has been reported in colorectal, breast, esophageal, pancreatic, oral, and gastric cancers and is frequently associated with adverse clinicopathological features, treatment resistance, metastatic behavior, and poor prognosis. Advances in microbiome profiling, spatial analysis, and single-cell technologies have begun to reveal how F. nucleatum colonizes tumors and interacts with host cells and tumor-associated microbial communities.  \nMain body: This review summarizes current evidence regarding the tumorassociated activities of F. nucleatum, with emphasis on its routes of tumor entry, spatiotemporal colonization patterns, adhesion- and glycan-dependent tropism, polymicrobial niche formation, and crosstalk with cancer cells and immune components. We discuss how F. nucleatum promotes oncogenic signaling, inflammatory amplification, genomic and epigenetic reprogramming, epithelial–mesenchymal transition, metastatic dissemination, immune evasion, and therapy adaptation. Particular attention is given to its context-dependent effects on chemotherapy, radiot","cbCaijfTfbe04Lfc","https://ap.wps.com/l/cbCaijfTfbe04Lfc","pdf",3616747,25,"English","# Key points\n# Introduction\n# Abstract\n## Background\n## Main body\n## Conclusion\n# Graphical Abstract\n## Tumour colonisation mechanisms\n## Cancer progression mechanisms\n## Therapy response and targeting","[{\"question\":\"Which cancers show increased intratumoral Fusobacterium nucleatum abundance, according to the abstract?\",\"answer\":\"Increased intratumoral abundance of Fusobacterium nucleatum has been reported in colorectal, breast, esophageal, pancreatic, oral, and gastric cancers.\"},{\"question\":\"How does Fusobacterium nucleatum promote cancer progression as summarized in the graphical abstract and key points?\",\"answer\":\"It promotes cancer progression through adhesion, inflammation, immune evasion, epigenetic remodelling, and metastasis.\"},{\"question\":\"What determines Fusobacterium nucleatum’s effects on therapy response?\",\"answer\":\"Its effects on therapy response are described as tumour-context dependent, with emphasis on chemotherapy, radiotherapy, and immunotherapy responses.\"}]","Fusobacterium nucleatum in cancer - Interactions with microbiota, tumour colonisation and cancer progression | PDF",1790109848,63,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d8f5da7cc956392cb4d2075b3618c7a.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd7d52ca73681ae8c2d4930bebafe43b.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71fedf56494af1a11b73749b410e1848.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b957b432086cede4d29dfe3a8b5c4ca.webp",980,1287]